



Smart Contracts and Petri Dishes

Creating a Shared Technical Infrastructure Roadmap for DeSci

Paul Kohlhaas

Co-Founder, Molecule & VitaDAO

Agenda .

1. Problems Definitions and Goals
2. What have we accomplished and learned
3. Where are we today
4. Hopes for the future
5. Workshop session and breakout groups



Problem Definition

“DeSci” has existed for around 1 year.



Problem Definition

crowd survey

DECENTRALIZED SCIENCE LANDSCAPE

Distributed Fundraising • On-chain Publishing • IP-NFTs • Quadratic funding • Retroactive public goods funding

DECENTRALIZED BIOTECH

-  Cloud Labs
STRATEOS, EMERALD
-  OpenNMN
-  DeBio
-  Open Therapeutics
-  Fleming Protocol
-  Perlara PBC
-  Framework Bio
-  Phage Directory
-  Innovative Bioresearch
-  Recerca
-  Molecule
-  Vibe Bio

SCIENCE DAOs

-  Bio DAO
-  Cherubs DAO
-  CRISPRDAO
-  CureDAO
-  DeNature DAO
-  Frontier DAO
-  GenomesDAO
-  HairDAO
-  LabDAO
-  NeuraDAO
-  OpScientia
OPEN SCIENCE DAO
-  PsyDAO
-  Research Collective
-  Research Hub DAO
-  ValleyDAO
-  VitaDAO

SCIENTIFIC PUBLISHING

-  Agora Labs
-  Flashpub
-  Ants Review
-  Planck
-  Atoms
-  Seeds of Science
-  Braid Science
-  TalentDAO

SCIENCE NFTs

-  Atomic Heart NFT
-  PLANT GANG
-  DNAVERSE
-  SameYou
-  Existential Hope
-  SpinalCordNFT
-  GENEnft
-  UltraRare Bio

DECENTRALIZED FUNDING OF SCIENCE

-  Antidote DAO
-  Gridcoin
-  Crowd Funded Cures
-  Impact Finance
-  DeSci Foundation
-  Moon Rabbit
-  Experiment
-  Science Fund
-  Gitcoin
-  SCINET
-  Giveth.io

FOUNDATIONS & INSTITUTES

-  Arc Institute
-  Convergent Research
-  Arcadia Institute
-  Foresight Institute
-  Astera Institute
-  New Science

COMMUNITIES & CHATS

-  Blockchain for Science
-  JustOneGiantLab
-  DeSci Nerdery Discord
-  Nuclease Dojo
-  DeSci World
-  Smart Contract Research Forum
-  Friendzymes
-  Web3 Women in Science

PROTOCOLS & DATA

-  Ocean Protocol
-  Protocol Labs

CURATED BY:

@UltraRareBio -@jocelynnpearl & @danielyse_
Designed by @katie_koczera



Problem Definition

We have an opportunity today to define the roadmap for future builders and create an open collaborative technical infrastructure.



Problem Definition

DeSci will be most successful if enabled as interoperable permissionless lego blocks.





What lego blocks
do we need?



For which types of
DeSci applications?

Science is full of problems.

Funding

Funding is highly competitive and asymmetrically distributed. Most scientists would change topics and fields if funding was not a concern. We spend too much time applying for it.

Replication

Much of science is not reproducible. We work in silos and often fail to report negative results. Much of science is built on invalid data. Incentives are perverse.

Competition

Science has become hyper-competitive, creating perverse incentives. The life of a young academic is incredibly stressful, publish or perish, and less than 2% of NIH funding to under 35 y/o's.

Comms

Science is inaccessible. Much of the important scientific literature lives behind paywalls, out of the reach of the population. Dissemination, peer-review, and access are broken.

Some problems stem from centralizing authorities.

Funding

Funding is largely centralized by governments with tax-dollar funding, yet the public is largely excluded from the decision-making process around what is funded.

Replication

Centralized scientific communities, which use similar methods and involve shared authors who contribute to many articles, propagate less replicable claims than decentralized communities


Competition

Competition for publishing, tenure track positions, and unilateral career movement is predicated on engagement with a few centralized and powerful agencies and universities.

Comms

Centralized authorities control access to information and determine the rules of how we communicate science and who reads them. These authorities have asymmetrical power.

What if science is decentralized?



Why is decentralization important?

Centralized institutions have played an important role in the facilitation of science, but can sometimes fall short.

Users participate in a trustless system

Lowers risk of systemic failure

Censorship resistance fosters an open culture.

Enables global collaboration

Why, what, and how DeSci?

01

Why

To build on the open science movement, make science more collaborative, and make science accessible to everyone.

02

What

A global, open alternative to the current scientific system that anyone can participate in.

03

How

Technology that enables scientists to raise funding, run experiments, share data, distribute insights, and more, openly.

DeSci Verticals

Areas that DeSci is currently targeting and attempting to disrupt.

O1 Funding of Data, IP and Impact

Faster, more democratic funding mechanisms that enable communities to form and govern impact and IP.

O2 Publishing

Transparent, open access publishing with aligned incentives. Peer review is incentivized.


O3 DAOs & Research Governance

DAOs present new ways of organising researcher or patient involvement and clinical trials.

O4 Identity and Reputation

Individuals to prove their experience and credentials linked to their Ethereum address for example.

Of these verticals,
funding and IP
are seeing the
most progress.



Funding + IP

The current standard model for funding science is that individuals or groups of scientists make written applications to a funding agency, or form a company to raise VC.

O1 Retroactive Public Goods Funding

Projects receive funding for achieving certain goals, created by the public.

O2 Quadratic Funding

A fairer, more democratic and balanced way to allocate funding to projects



O3 DAOs/Tokenized Incentive Structures

Communities vote to decide how funding is allocated. They govern over projects.

O4 IP-NFTs

Ownership in research related IP as an incentive for funding and collaboration.


Example: Innovation & Biotech Research Today



IP and Patents are Legacy Legal Physical Assets.

1. Bureaucratic and outdated IP systems make IP hard to transact
2. Often too expensive to structure and negotiate early stage IP
3. Fuels the Valley of Death as IP gets shelved due to inefficiency

Data and Software is Virtual.



Example: USPTO Patent Search

Searching US Patent Collection...

Results of Search in US Patent Collection db for:
psilocybin: 921 patents.
Hits 1 through 50 out of 921

Next 50 Hits

Jump To:

Refine Search: psilocybin

PAT. NO. Title

- 1 [11,441,164](#) Biosynthetic production of psilocybin and related intermediates in recombinant organisms
- 2 [11,440,879](#) Methods of treating mood disorders
- 3 [11,432,772](#) Systems and methods for replacing signal artifacts in a glucose sensor data stream
- 4 [11,427,604](#) Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
- 5 [11,426,400](#) Methods of increasing satellite cell proliferation with vorinostat or bosutinib
- 6 [11,426,367](#) Methods of treating substance abuse
- 7 [11,420,967](#) Modified carbazoles as therapeutic agents
- 8 [11,419,280](#) Methods of crossbreeding fungi organisms
- 9 [11,414,423](#) Substituted 1,2,3,4,5,6-hexahydroazezepino[4,5-b]indoles for treating brain disorders
- 10 [11,412,966](#) Transcutaneous analyte sensor systems and methods
- 11 [11,406,619](#) Injectable formulations
- 12 [11,400,101](#) Methods for inhibiting microbe growth
- 13 [11,399,745](#) Dual electrode system for a continuous analyte sensor
- 14 [11,399,742](#) Systems and methods for a continuous monitoring of analyte values
- 15 [11,395,824](#) 5-HT_{2C} receptor agonists and compositions and methods of use
- 16 [11,395,631](#) Transcutaneous analyte sensors, applicators therefor, and associated methods

United States Patent
Stella, et al.

Modified carbazoles as therapeutic agents

Abstract

This disclosure relates to compounds that target microtubules, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases. More particularly, this disclosure relates to pharmaceutical compositions thereof, methods of targeting microtubules with these compounds, and methods of treating diseases affected by microtubule disruption.

Inventors: Stella; Nephi (Seattle, WA), Diaz; Philippe (Missoula, MT)
Applicant: Name City State Country Type

UNIVERSITY OF WASHINGTON	Seattle	WA	US
THE UNIVERSITY OF MONTANA	Missoula	MT	US

Assignee: UNIVERSITY OF WASHINGTON (Seattle, WA)
THE UNIVERSITY OF MONTANA (Missoula, MT)

Family ID: 67253979
Appl. No.: 16/960,541
Filed: June 12, 2019
PCT Filed: June 12, 2019
PCT No.: PCT/US2019/036860
371(c)(1),(2),(4) Date: July 07, 2020
PCT Pub. No.: WO2019/241451
PCT Pub. Date: December 19, 2019

Prior Publication Data

Document Identifier: US 20210094949 A1


Publication Date: Apr 1, 2021

Related U.S. Patent Documents

Application Number	Filing Date	Patent Number
62683953	Jun 12, 2018	
62714436	Aug 3, 2018	


IP monopolies kill innovation – and lead to high drug prices

- Restricts scientific collaboration and "discoverability of IP" as organisations work in siloes.
- Limits open science, creates reproducibility crisis as negative data is buried.
- Rather than the best science, revenue-drivers dominate medicine.




What could a
different system
look like?

Towards an open
market for IP



Most of the world's potential scientific talent remains untapped.

Let's enable a Creator Economy for Scientists...



Molecule's Mission: Realigning Incentives via Decentralised Biotech


Towards an open
transparent market for
research funding

The screenshot displays the Molecule platform's user interface. At the top, there is a navigation bar with the Molecule logo, 'Discover Projects', 'My Projects', 'Create a Project', 'Molecule Admin', and a user profile icon. Below the navigation bar is a search bar labeled 'Search Projects' and several filter buttons: 'VitaDAO', 'Therapeutic Area', 'Opportunity Type', and 'Clinical Stage'. The main content area is titled 'All Research Projects' with the subtitle 'Discover early-stage drug development funding, collaboration and licensing opportunities.' A dropdown menu 'Sort By Newest' is visible. The page features a grid of six research project cards, each with a thumbnail, title, brief description, and details about licensing partners and clinical stages.

Project Title	Licensing Partners	Clinical Stage
Novel Small Molecules for Alzheimer's Disease	University of Rochester and NIA	Preclinical
Therapeutic and Prophylactic for Arthritis	The University of Toledo and NIA	Preclinical
Osterix Specific Peptides	UC Davis and NIA	Preclinical
Serum Serotonin Inhibitors for the Treatment of Osteoporosis	Columbia University and NIA	Preclinical
Method Against Degenerative Diseases and Ageing Processes	Rutgers University and NIA	Preclinical
New Molecular Target Mechanism in Ageing-Related Sarcopenia	Universiteit Leiden and NIA	Preclinical

How do we bring legal IP and Data into Web3?

A DeSci Lego Block: IP-NFTs



Anatomy of IP-NFTs

1. **Legal** - legal contracts & license tied to real-world research or data
2. **Storage** - decentralised permanent data storage, public and private data repos
3. **Transactability** - seamless transfer of IP
4. **Discoverability** - via public metadata
5. **Programmability of IP**
 - a. **Governance**
 - b. **Fractionalisation (FRENS framework)**
 - c. **Programmatic royalties**
 - d. **Pay-for-success models**

Discover Create a Project

Project Inquiry View IP-NFT Save Share This

Amit Sharma

SENB Research Foundation US

Clinical Stage Early Stage

Patent Status Patent not filed

Opportunity type Funding requested \$430,000

Background


ApotoSENS - Senolytic CAR-NK cells

Aging

Over time, a subset of cells in our body experience damage and enter a state of senescence. Cellular senescence is the irreversible arrest of proliferation accompanied by proinflammatory factors that lead to tissue dysfunction. Selective elimination of these senescent cells has been shown to ameliorate hallmarks of aging in both mice and humans. However, current methods to eliminate senescent cells are non-specific and may have off-target effects. As a result, we are developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells to precisely and safely eliminate senescent cells *in vivo*.

Overview Market Opportunity Discussion

Anatomy of IP-NFTs



IP-NFTs are composable Web3 building blocks



1. Can be transacted like NFTs and applied in funding
2. DAOs can now build portfolios of research (Bio DAOs)
3. NFTs can be fractionalised and act as DeFi lego blocks
4. Data access can be granted via multi-sigs

Only scratching the surface...


DeSci Web3 Lego Blocks

01 Transaction Layers

02 Data Storage Layers

03 Compute & Execution Layers

04 Identity Layers



Workshop Goals

The goal of this workshop will be **to explore how decentralized science can improve the process of funding, doing, and disseminating science through the use of decentralized systems.**

Groups can break into the following verticals to explore the problem space and brainstorm solutions:

1. Funding and IP
2. Data and Reproducibility
3. Publishing
4. Identity and Reputation

Workshop Flow

Setting the Scene (20min)

Breakout 1 (40min)

Breakout Pitches (10min)

Discussion (40min)

Call to Action (10min)



Workshop and Breakouts



DeSci Verticals

Areas that DeSci is currently targeting and attempting to disrupt.

O1 Funding of Data, IP and Impact

Faster, more democratic funding mechanisms that enable communities to form and govern impact and IP.

O2 Publishing

Transparent, open access publishing with aligned incentives. Peer review is incentivized.

O3 DAOs & Research Governance

DAOs present new ways of organising researcher or patient involvement and clinical trials.

O4 Identity and Reputation

Individuals to prove their experience and credentials linked to their Ethereum address for example.



Thank you!

Paul Kohlhaas

Co-Founder, Molecule & VitaDAO

paul@molecule.to



@paulkhls